AI-Guided Radiation Therapy for Stomach Lymphoma
Part of Cancer, Digestive system clinical trials.
This trial tests a new computer-assisted radiation therapy approach for early-stage lymphoma (cancer) in the stomach. The AI system helps doctors customize and adjust your radiation treatment in real-time, potentially improving outcomes and reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary gastric lymphoma (a lymph-cell cancer starting in the stomach) that is stage I, II, or IIE
- Your doctor believes radiation therapy is the right treatment for you, either as your main treatment or after chemotherapy
- You are between 18 and 75 years old
- You are in good enough health to tolerate radiation (ECOG performance status 0–1, meaning you can do most normal activities)
- Your heart, liver, kidneys, and blood counts are working well enough for this treatment
- You have not had radiation to your belly or pelvis in the last 3 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation and an oral targeted therapy (orelabrutinib) for patients with a slow-growing type of lymphoma called MALT lymphoma. The goal is to see if this approach can effectively treat the disease while reducing side effects.
This study tests whether a specific course of focused radiation (20 Gy) can control indolent (slow-growing) lymphoma in the stomach or upper small intestine. It may help shrink or stabilize tumors and lymph node involvement while limiting side effects.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of chemotherapy (conversion therapy), surgery, and radiation for people with stomach cancer that has spread only to lymph nodes behind the stomach. The goal is to see if this approach can help shrink the cancer and improve outcomes.
This trial tests a combination of low-dose radiotherapy, chemotherapy, and an immunotherapy drug (tislelizumab) before and after surgery for locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
This trial tests combining an immunotherapy drug (sintilimab) with low-dose radiation before surgery for stomach cancer that has a specific genetic marker (dMMR/MSI-H). The goal is to see if this combination can shrink the tumor and improve outcomes without needing strong chemo.
Hear when a new Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.